Seguir
Francisco Javier Pavón
Francisco Javier Pavón
MSII and Nicolás Monardes Researcher - IBIMA
Dirección de correo verificada de ibima.eu
Título
Citado por
Citado por
Año
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
JZ Long, W Li, L Booker, JJ Burston, SG Kinsey, JE Schlosburg, FJ Pavón, ...
Nature chemical biology 5 (1), 37-44, 2009
10292009
A genetic determinant of the striatal dopamine response to alcohol in men
VA Ramchandani, J Umhau, FJ Pavon, V Ruiz-Velasco, W Margas, H Sun, ...
Molecular psychiatry 16 (8), 809-817, 2011
3222011
Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-3-hexyl-1H-1, 2, 4-triazole–LH 21
FJ Pavon, A Bilbao, L Hernández-Folgado, A Cippitelli, N Jagerovic, ...
Neuropharmacology 51 (2), 358-366, 2006
1342006
Oleoylethanolamide prevents neuroimmune HMGB1/TLR4/NF‐kB danger signaling in rat frontal cortex and depressive‐like behavior induced by ethanol binge administration
M Antón, F Alén, R Gomez de Heras, A Serrano, FJ Pavón, JC Leza, ...
Addiction biology 22 (3), 724-741, 2017
1082017
Plasma profile of pro‐inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co‐morbidity
P Araos, M Pedraz, A Serrano, M Lucena, V Barrios, N García‐Marchena, ...
Addiction biology 20 (4), 756-772, 2015
1072015
Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats
A Sayd, M Antón, F Alén, JR Caso, J Pavón, JC Leza, ...
International Journal of Neuropsychopharmacology 18 (6), pyu111, 2015
1062015
Peroxisome proliferator-activated receptors: Experimental targeting for the treatment of inflammatory bowel diseases
J Decara, P Rivera, AJ López-Gambero, A Serrano, FJ Pavón, E Baixeras, ...
Frontiers in pharmacology 11, 493292, 2020
1022020
Reduction of body weight, liver steatosis and expression of stearoyl‐CoA desaturase 1 by the isoflavone daidzein in diet‐induced obesity
A Crespillo, M Alonso, M Vida, FJ Pavón, A Serrano, P Rivera, ...
British journal of pharmacology 164 (7), 1899-1915, 2011
992011
A place for the hippocampus in the cocaine addiction circuit: Potential roles for adult hippocampal neurogenesis
E Castilla-Ortega, A Serrano, E Blanco, P Araos, J Suárez, FJ Pavon, ...
Neuroscience & Biobehavioral Reviews 66, 15-32, 2016
942016
Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH‐21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats
FJ Pavon, A Serrano, V Perez‐Valero, N Jagerovic, ...
Journal of neuroendocrinology 20, 116-123, 2008
942008
The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats
A Serrano, I Del Arco, FJ Pavón, M Macías, V Perez-Valero, ...
Neuropharmacology 54 (1), 226-234, 2008
912008
Pharmacological administration of the isoflavone daidzein enhances cell proliferation and reduces high fat diet-induced apoptosis and gliosis in the rat hippocampus
P Rivera, M Pérez-Martín, FJ Pavón, A Serrano, A Crespillo, M Cifuentes, ...
PLoS One 8 (5), e64750, 2013
812013
Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system‐related genes in the rat amygdala
A Serrano, P Rivera, FJ Pavon, J Decara, J Suárez, ...
Alcoholism: Clinical and Experimental Research 36 (6), 984-994, 2012
792012
Role of the satiety factor oleoylethanolamide in alcoholism
A Bilbao, A Serrano, A Cippitelli, FJ Pavón, A Giuffrida, J Suárez, ...
Addiction biology 21 (4), 859-872, 2016
772016
Oleoylethanolamide, neuroinflammation, and alcohol abuse
L Orio, F Alen, FJ Pavón, A Serrano, B García-Bueno
Frontiers in molecular neuroscience 11, 427528, 2019
722019
Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat
J Suárez, P Rivera, S Arrabal, A Crespillo, A Serrano, E Baixeras, ...
Disease models & mechanisms 7 (1), 129-141, 2014
722014
Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake
A Serrano, FJ Pavon, MW Buczynski, J Schlosburg, LA Natividad, IY Polis, ...
Neuropsychopharmacology 43 (9), 1840-1850, 2018
682018
Anti‐obesity efficacy of LH‐21, a cannabinoid CB1 receptor antagonist with poor brain penetration, in diet‐induced obese rats
M Alonso, A Serrano, M Vida, A Crespillo, L Hernandez‐Folgado, ...
British journal of pharmacology 165 (7), 2274-2291, 2012
672012
Effects of the endogenous PPAR‐α agonist, oleoylethanolamide on MDMA‐induced cognitive deficits in mice
A Plaza‐Zabala, F Berrendero, J Suarez, FJ Bermudez‐Silva, ...
Synapse 64 (5), 379-389, 2010
592010
Alcohol‐induced cognitive deficits are associated with decreased circulating levels of the neurotrophin BDNF in humans and rats
D Silva‐Peña, N García‐Marchena, F Alén, P Araos, P Rivera, A Vargas, ...
Addiction biology 24 (5), 1019-1033, 2019
562019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20